Hydroxyethyl Starch

Hydroxyethyl Starch Market Outlook

The global Hydroxyethyl Starch (HES) market is projected to reach approximately USD 2.5 billion by 2035, with a compound annual growth rate (CAGR) of about 4.5% during the forecast period from 2025 to 2035. The growing demand for intravenous (IV) solutions in healthcare settings, particularly in fluid resuscitation and surgical procedures, is a critical growth factor propelling the HES market. Additionally, advancements in manufacturing processes and increasing healthcare expenditure in emerging economies are expected to provide significant opportunities for market expansion. Furthermore, the rising prevalence of chronic diseases and trauma cases, leading to higher hospital admissions, is boosting the demand for blood plasma volume expanders like Hydroxyethyl Starch. The market is also witnessing a surge in research and development activities aimed at enhancing the safety and efficacy profiles of HES products.

Growth Factor of the Market

One of the primary drivers of the Hydroxyethyl Starch market is the increasing adoption of advanced surgical procedures that require effective volume expanders to maintain hemodynamic stability in patients. These surgical procedures, including orthopedic, cardiovascular, and trauma surgeries, necessitate the use of reliable products like HES for fluid management. Furthermore, the rising incidence of surgical interventions due to the aging population and the prevalence of lifestyle-related diseases has led to an increased demand for effective blood volume expansion solutions. The regulatory bodies' approval for new HES formulations that provide enhanced performance and reduced adverse reactions is also significantly contributing to market growth. Moreover, the trend towards personalized medicine is encouraging manufacturers to innovate and develop tailored HES solutions catering to specific patient needs. The expansion of distribution channels and the growing emphasis on patient-centric healthcare solutions are further driving the market forward.

Key Highlights of the Market

• The Hydroxyethyl Starch market is expected to see a significant rise in demand due to the increased need for IV fluids in surgical settings.
• Emerging markets are likely to become key players in the HES market due to rising healthcare infrastructure investments.
• Continued innovations in HES formulations, focusing on safety and performance, are expected to enhance market appeal.
• Regulatory changes and approvals are paving the way for the introduction of more advanced HES products.
• The growing trend of minimally invasive surgeries is driving the demand for efficient volume expanders like HES.

By Product Type

Hydroxyethyl Starch 6%:

Hydroxyethyl Starch 6% is widely utilized in clinical settings due to its balanced osmotic properties and low incidence of adverse effects. This concentration is particularly effective for volume expansion in patients with hypovolemia or undergoing major surgeries. The product is known for its ability to maintain hemodynamic stability, which is crucial in surgical and trauma care. The HES 6% solution is often preferred in environments where rapid volume replacement is necessary, making it a staple in emergency medical services and surgical units. Its safety profile and efficacy continue to drive its adoption across various healthcare facilities.

Hydroxyethyl Starch 10%:

The Hydroxyethyl Starch 10% solution is designed for patients needing moderate fluid resuscitation. It is often used in critical care settings where there is a need for effective plasma volume expansion without inducing significant fluid overload. This product type is particularly beneficial in managing patients with septic shock, where rapid fluid replenishment is critical for survival. Its properties allow for extended intravascular retention, making it suitable for prolonged use in intensive care units. As healthcare providers seek effective and safe volume expanders, the market for HES 10% is anticipated to grow steadily.

Hydroxyethyl Starch 20%:

Hydroxyethyl Starch 20% is primarily employed in specialized clinical scenarios where a higher concentration of volume expanders is warranted. This product is particularly favored in specific surgical interventions and critical care situations. Due to its higher osmotic potential, it is effective in rapidly expanding plasma volume, making it suitable for use in major surgeries or trauma cases. However, the utilization of HES 20% requires careful monitoring due to potential side effects like renal impairment, which necessitates a strategic approach in patient management. As awareness of the importance of volume status in critical care increases, the demand for HES 20% is expected to grow.

Hydroxyethyl Starch 30%:

Hydroxyethyl Starch 30% caters to a niche market, where extreme volume expansion is required. This concentration is often utilized in highly specialized medical procedures and intensive care environments. The ability to provide a significant boost in plasma volume makes it an indispensable tool in managing complex medical cases, including severe hemorrhagic shock. Its use is, however, restricted to settings where patient monitoring is optimally organized, given the associated risks of adverse effects. The development of HES 30% formulations is a response to the evolving needs of intensive care medicine, paving the way for its sustained demand in high-acuity settings.

Hydroxyethyl Starch 40%:

Hydroxyethyl Starch 40% findings its applications primarily in research and experimental settings due to its high concentration and specific use cases. This product is relatively less common in routine clinical practice due to the risks associated with higher starch levels and the potential for complications. However, its role in developing advanced therapeutic strategies and understanding volume resuscitation mechanisms cannot be overlooked. As the research community continues to explore the properties and benefits of high-concentration HES solutions, there may be future opportunities for its adoption in clinical settings.

By Application

Fluid Volume Expansion:

The application of Hydroxyethyl Starch for fluid volume expansion is one of its primary uses in medical practice. This solution is essential for patients experiencing hypovolemia due to trauma, surgery, or severe dehydration. The ability of HES to expand plasma volume quickly is crucial in emergencies where fluid loss can lead to shock and poor outcomes. The effectiveness of HES in restoring hemodynamic stability enables clinicians to stabilize patients significantly faster than traditional crystalloid solutions. Additionally, the pharmacokinetics of HES allow for prolonged intravascular retention, providing sustained support during critical phases of recovery. As the need for effective volume expanders grows, this application is expected to remain a cornerstone for HES usage.

Blood Plasma Volume Expansion:

Blood plasma volume expansion is another vital application of Hydroxyethyl Starch, particularly in perioperative care. Its role in maintaining adequate plasma levels during surgical procedures cannot be overstated, as it helps mitigate the risks associated with blood loss and fluid shifts. By effectively replacing lost plasma volume, HES contributes to improved outcomes in surgical patients, particularly those undergoing extensive operations. Furthermore, it allows for the management of patients with bleeding disorders or those requiring significant fluid resuscitation. As the surgical landscape evolves, the reliance on HES for blood plasma volume expansion continues to support its demand in healthcare systems.

Others:

The "Others" category encompasses additional applications of Hydroxyethyl Starch, including its use in research settings and investigational studies aimed at exploring its efficacy in various medical scenarios. HES is increasingly being examined for potential roles outside traditional volume expansion, such as its application in drug delivery systems or its potential benefits in managing certain chronic conditions. Ongoing research may unveil novel uses for Hydroxyethyl Starch, expanding its marketability and applications in the medical field. This potential for diversification in use keeps the market dynamic and responsive to evolving medical needs.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for Hydroxyethyl Starch, given their central role in patient care and emergency management. The demand for HES in hospitals is driven by the need for effective volume expanders for surgical procedures and critical care situations. Hospitals typically have established protocols for administering HES solutions, ensuring that they are utilized efficiently and safely. The availability of HES products in hospitals supports a rapid response to patient needs, especially in emergency departments and operating rooms. Moreover, hospitals often engage in bulk purchasing agreements with suppliers, ensuring a steady supply of these essential products.

Clinics:

Clinics serve as another important distribution channel for Hydroxyethyl Starch, particularly those specializing in outpatient surgical procedures or infusion therapy. The increasing trend of outpatient surgeries has resulted in a growing demand for effective volume expanders, making HES an essential component in clinical practice. Clinics often utilize HES for fluid management in patients requiring immediate care or those undergoing minor surgical interventions. As healthcare delivery shifts towards outpatient settings, the role of clinics in distributing and utilizing Hydroxyethyl Starch is expected to expand further, driving growth in this segment.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are specialized facilities that perform surgical procedures on an outpatient basis, and they are becoming an increasingly significant distribution channel for Hydroxyethyl Starch. The growth of ASCs is fueled by the rising preference for minimally invasive surgeries that require quick recovery and efficient post-operative care. The ability of HES to support effective fluid management in these settings ensures that patients receive optimal care while minimizing the risks associated with fluid loss during procedures. As the number of ASCs increases and their services expand, the demand for HES products is expected to grow correspondingly.

Others:

The "Others" category includes alternative distribution channels for Hydroxyethyl Starch, such as online pharmacies and specialized medical supply providers. As e-commerce continues to gain traction within the healthcare sector, the accessibility of HES through online platforms is expected to increase. This trend facilitates the procurement of HES products for smaller healthcare facilities and practitioners who may not have direct access to large suppliers. Additionally, pharmaceutical distributors and wholesalers play a vital role in ensuring that HES products reach various healthcare settings efficiently. The diversification of distribution channels for Hydroxyethyl Starch supports the overall growth of the market.

By Ingredient Type

Corn:

Corn is one of the primary ingredient sources used in the production of Hydroxyethyl Starch. Its widespread availability and cost-effectiveness make it a popular choice for manufacturers. Corn-derived HES is favored for its high purity levels and the ability to achieve the desired viscosity required for various applications. The starch extracted from corn is modified to create HES solutions that meet specific medical standards. Moreover, as corn is a staple crop in many regions, the supply chain for corn-based HES is relatively stable, supporting uninterrupted production for healthcare needs. The continuous demand for corn-based products in the food and pharmaceutical sectors further reinforces its position in the HES market.

Potato:

Potato starch is another significant ingredient used in the production of Hydroxyethyl Starch, valued for its unique properties. Potato-derived HES exhibits excellent thickening and binding capabilities, making it suitable for various pharmaceutical applications. The use of potato starch in HES formulations is often aligned with the production of specialty products that demand specific functional characteristics. Additionally, the market for potato starch is experiencing growth due to the increasing application of potato-based products in the food and beverage industry, which can indirectly benefit HES manufacturers by ensuring a robust supply chain. The versatility and functionality of potato starch contribute positively to the expansion of the Hydroxyethyl Starch market.

Sorghum:

Sorghum is an emerging ingredient type for Hydroxyethyl Starch production, particularly in regions where it is cultivated extensively. This ingredient offers an alternative to traditional starch sources, catering to diverse consumer demands, including those seeking gluten-free options. Sorghum-derived HES is being explored for its potential health benefits and functional properties in various medical applications. The increasing awareness of sorghum as a nutritious and versatile crop is driving interest in its use for HES formulations, potentially expanding the market share of this ingredient type. The growth of sorghum in the agricultural sector presents new opportunities for HES manufacturers to diversify their ingredient sourcing.

Wheat:

Wheat starch is also utilized in the production of Hydroxyethyl Starch, known for its broad availability and favorable properties. Wheat-derived HES is recognized for its ability to achieve desired viscosity and stability in various formulations. The significance of wheat as a staple crop ensures a consistent supply for HES production, supporting the growth of this ingredient type in the market. However, wheat-derived products are subject to gluten-related concerns, which may limit their appeal in certain consumer segments. Manufacturers focusing on transparency and safety in ingredient sourcing can leverage wheat-based HES effectively while addressing potential market challenges.

Others:

The "Others" category encompasses various alternative starch sources used in Hydroxyethyl Starch production, including tapioca and rice. These ingredients are gaining traction due to their functional properties and demand for specialty products. As the market for plant-based and alternative ingredient solutions grows, the use of diverse starch sources for HES formulations is expected to increase. Manufacturers exploring innovative approaches to ingredient sourcing can capitalize on this trend, enhancing their product offerings and catering to a broader market. The evolution of consumer preferences toward healthier and more sustainable ingredients will likely drive growth in the "Others" segment.

By Region

The regional analysis of the Hydroxyethyl Starch market reveals distinct trends and growth trajectories across various geographical areas. North America leads the market, accounting for approximately 40% of the global share, driven by advanced healthcare systems and a high prevalence of surgical procedures. The robust presence of key players in the pharmaceutical industry and the increasing demand for effective volume expanders in critical care settings contribute significantly to this regional dominance. Furthermore, the expansion of outpatient surgical centers and the rise in minimally invasive surgical procedures are expected to bolster the Hydroxyethyl Starch market in North America, with a projected CAGR of 5.2% over the forecast period.

In Europe, the Hydroxyethyl Starch market is also witnessing steady growth, attributed to the increasing adoption of advanced medical technologies and rising healthcare expenditure. The region holds around 30% of the global market share, with significant contributions from countries such as Germany, France, and the UK. The growing emphasis on patient safety and the development of innovative HES formulations are driving demand in this region. Additionally, the increasing prevalence of chronic diseases and the aging population are fostering a conducive environment for the expansion of the HES market in Europe. The Asia Pacific region, with its expanding healthcare infrastructure and rising awareness regarding fluid management, is expected to emerge as a key player in the coming years, potentially capturing around 20% of the market share.

Opportunities

The Hydroxyethyl Starch market is poised for significant growth due to several emerging opportunities. One of the primary opportunities lies in the expansion of healthcare facilities in developing regions, which is paving the way for enhanced access to critical care products, including HES. As countries invest in upgrading their healthcare infrastructure, the demand for intravenous fluids and effective volume expanders is expected to surge. This presents a substantial opportunity for manufacturers to establish a foothold in these markets by offering innovative HES solutions tailored to local healthcare needs. Additionally, the growing trend of personalized medicine and the focus on patient-centric therapies can lead to the development of customized HES formulations that cater to specific patient conditions, further propelling market growth.

Moreover, the increasing emphasis on research and development in the field of intravenous fluid management is opening new avenues for innovation. A growing body of clinical evidence supporting the efficacy and safety of Hydroxyethyl Starch as a volume expander is likely to enhance its acceptance among healthcare professionals. Furthermore, partnerships between pharmaceutical manufacturers and research institutions can facilitate the development of novel HES formulations, enhancing therapeutic outcomes. The rising demand for safe and effective alternatives to traditional volume expanders, driven by changing patient demographics and evolving medical practices, will likely create further opportunities for HES in the market.

Threats

The Hydroxyethyl Starch market faces certain threats that could impact its growth trajectory. One major concern is the increasing scrutiny and regulatory challenges surrounding the use of HES solutions, particularly in light of associated adverse effects such as renal impairment and coagulopathy. Regulatory agencies are becoming more vigilant in assessing the safety profiles of intravenous fluids, which may lead to stricter guidelines and restrictions on HES usage. This evolving regulatory landscape poses a challenge for manufacturers who must navigate compliance while ensuring product efficacy. As more healthcare providers explore alternatives to HES in response to safety concerns, the market may experience a shift in demand that could hinder growth.

Additionally, the emergence of alternative volume expanders and the increasing preference for crystalloids over colloids in certain clinical scenarios present threats to the Hydroxyethyl Starch market. The growing body of clinical guidelines advocating for the use of isotonic crystalloids in fluid resuscitation may reduce the reliance on HES solutions. This shift in clinical practice could negatively impact sales and market penetration for HES products. As the competitive landscape evolves, manufacturers will need to adapt and innovate to address changing healthcare provider preferences and market dynamics.

Competitor Outlook

• Baxter International Inc.
• Fresenius Kabi AG
• B. Braun Melsungen AG
• Grifols S.A.
• Heska Corporation
• Otsuka Pharmaceutical Co., Ltd.
• Roche Diagnostics
• Octapharma AG
• Terumo Corporation
• Sichuan Kelun Pharmaceutical Co., Ltd.
• Hua Dong Medicine Co., Ltd.
• Hanjin Pharmaceutical Co., Ltd.
• Merck KGaA
• Pfizer Inc.
• Wockhardt Ltd.

The competitive landscape of the Hydroxyethyl Starch market is characterized by a mix of established pharmaceutical companies and emerging players striving to capture market share. Major players such as Baxter International Inc., Fresenius Kabi AG, and B. Braun Melsungen AG dominate the market with their extensive portfolios of HES formulations and strong distribution networks. These companies invest heavily in research and development, focusing on improving the safety and efficacy of HES products while ensuring compliance with regulatory standards. Additionally, partnerships and collaborations among these key players are becoming increasingly common as they seek to enhance their competitive edge and expand their product offerings.

As the Hydroxyethyl Starch market continues to evolve, competition is expected to intensify, particularly with the entry of new players offering innovative solutions. Companies like Grifols S.A. and Octapharma AG are gaining traction by introducing advanced HES formulations that address safety concerns while meeting clinical needs. The growing emphasis on personalized healthcare solutions and patient safety is prompting manufacturers to adapt their strategies and explore new product developments that resonate with healthcare providers and patients alike. The ability to differentiate through unique product attributes, effective marketing strategies, and solid clinical evidence will be essential for companies aiming to thrive in this competitive landscape.

Several emerging players are also entering the Hydroxyethyl Starch market, capitalizing on the increasing demand for effective volume expanders. Companies like Heska Corporation and Terumo Corporation are focusing on niche segments and exploring alternative ingredient sources to create innovative HES formulations. These smaller players may disrupt traditional market dynamics by offering tailored solutions that cater to specific clinical requirements. As the market landscape becomes more competitive, established players will need to remain agile and responsive to consumer demand while balancing innovation with regulatory compliance to maintain their market position.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Pfizer Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Grifols S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Octapharma AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Wockhardt Ltd.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Fresenius Kabi AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Heska Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Diagnostics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Terumo Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 B. Braun Melsungen AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Baxter International Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hua Dong Medicine Co., Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hanjin Pharmaceutical Co., Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Otsuka Pharmaceutical Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Sichuan Kelun Pharmaceutical Co., Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Hydroxyethyl Starch Market, By Application
    • 6.1.1 Fluid Volume Expansion
    • 6.1.2 Blood Plasma Volume Expansion
    • 6.1.3 Others
  • 6.2 Hydroxyethyl Starch Market, By Product Type
    • 6.2.1 Hydroxyethyl Starch 6%
    • 6.2.2 Hydroxyethyl Starch 10%
    • 6.2.3 Hydroxyethyl Starch 20%
    • 6.2.4 Hydroxyethyl Starch 30%
    • 6.2.5 Hydroxyethyl Starch 40%
  • 6.3 Hydroxyethyl Starch Market, By Ingredient Type
    • 6.3.1 Corn
    • 6.3.2 Potato
    • 6.3.3 Sorghum
    • 6.3.4 Wheat
    • 6.3.5 Others
  • 6.4 Hydroxyethyl Starch Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Hydroxyethyl Starch Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Hydroxyethyl Starch market is categorized based on

By Product Type

• Hydroxyethyl Starch 6%
• Hydroxyethyl Starch 10%
• Hydroxyethyl Starch 20%
• Hydroxyethyl Starch 30%
• Hydroxyethyl Starch 40%

By Application

• Fluid Volume Expansion
• Blood Plasma Volume Expansion
• Others

By Distribution Channel

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others

By Ingredient Type

• Corn
• Potato
• Sorghum
• Wheat
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Baxter International Inc.
• Fresenius Kabi AG
• B. Braun Melsungen AG
• Grifols S.A.
• Heska Corporation
• Otsuka Pharmaceutical Co., Ltd.
• Roche Diagnostics
• Octapharma AG
• Terumo Corporation
• Sichuan Kelun Pharmaceutical Co., Ltd.
• Hua Dong Medicine Co., Ltd.
• Hanjin Pharmaceutical Co., Ltd.
• Merck KGaA
• Pfizer Inc.
• Wockhardt Ltd.